Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD58m

    Last close

    USD0.62

    ▲ −0.06 (−8.28%)

    Creotech Instruments

    MCap

    PLN346m

    Last close

    PLN174.00

    ▲ 0.00 (0.00%)

    Creo Medical

    MCap

    GBP79m

    Last close

    GBP0.19

    ▲ −0.25 (−1.30%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Key opinion leader webinar: Context Therapeutics

Key opinion leader webinar: Context Therapeutics

Context Therapeutics — 4 videos in collection

More on this equity

Context Therapeutics (Nasdaq: CNTX) is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The company’s robust clinical programme for lead candidate onapristone extended release (ONA-XR) comprises three Phase II clinical trials and one Phase Ib/II clinical trial in hormone-driven breast, ovarian and endometrial cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. In this webinar, Context’s team and presenters from the American Association for Cancer Research (AACR) conference discuss the important company results presented at the AACR Annual Meeting 2022.

< Previous
Next >

You may also be interested in these:

Healthcare

Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data update

Healthcare

Context Therapeutics: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free